Kodiak reported Q4 results yesterday”Kodiak’s momentum has continued to build, highlighted by positive Phase 3 topline results from the GLOW2 study and multiple advancing late-stage and pipeline programs that together reinforce the company’s differentiated molecules, platform and long term growth strategy,” said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences (KOD).
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD:
- Kodiak Sciences rises 10.7%
- 3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
- Reiterating Buy on Kodiak: GLOW2 Validates Zenkuda’s Durable Efficacy and Multi‑Indication Path to Accelerated BLA
- Kodiak Sciences options imply 7.3% move in share price post-earnings
- Kodiak Sciences price target raised to $80 from $50 at UBS